Xcout Intel
Cayuga Biotech competitors & alternatives
The 12 closest competitors and alternatives to Cayuga Biotech among biotechnology companies — ranked by similarity to what Cayuga Biotech actually does, not by market-cap band.
Subscribe to see Cayuga Biotech’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Cayuga Biotech
Cayuga Biotech is a biotechnology company developing novel therapies to address life-threatening hemorrhage by harnessing the body's innate ability to stop bleeding.
Cayuga Biotech at a glance
Cayuga Biotech is a biotechnology company. Xcout tracks 16 named people at Cayuga Biotech, including Andrea Ashford-Hicks (Chief Executive Officer).
Cayuga Biotech leadership
- Andrea Ashford-HicksChief Executive Officer
- Damien KudelaFounder, Chief Science Officer
- Kyle PloensePreclinical Research
- Ajay RaiCorporate Development
- Charlie PollackClinical Development
- Genmin LuTranslational Medicine
10 more named people on record for Cayuga Biotech, with roles, board committees and tenure — see the full roster →
Top 12 Cayuga Biotech competitors
Ranked by semantic similarity — how close each company is to Cayuga Biotech by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Healthcare Biotech
HemostOD is a preclinical-stage biotech company based in Lausanne, Switzerland, pioneering the ex vivo manufacturing of donor-free, off-the-shelf universal human blood platelets to save lives.
Biotech
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Similar biotechnology company
Hemoglobin Oxygen Therapeutics LLC develops oxygen-carrying solutions, such as its Hemopure product, for medical applications including organ transplants and preservation. The company serves the healthcare and medical research sectors by providing hemoglobin-based therapeutics used in clinical studies and surgical procedures.
Similar biotechnology company
Rallybio is a clinical-stage biotechnology company that develops therapies for patients with severe and rare diseases, focusing on areas such as complement dysregulation and hematology. The company's pipeline includes therapeutic assets like C5 inhibitors designed to address significant unmet medical needs.
BioTech
Acticor Biotech is a clinical-stage biopharmaceutical company headquartered in Paris, France, that specializes in developing innovative treatments for acute thrombotic diseases.
Biotech
Aptahem AB is a clinical-stage biotechnology company that develops RNA-based pharmaceuticals, also known as aptamers, for the treatment of acute conditions such as sepsis.
Biotech
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Similar biotechnology company
Inotrem is a French clinical-stage biotechnology company developing therapies for dysregulated innate immune responses and inflammation. Its lead candidate, nangibotide (LR12), targets TREM-1 and has been investigated for severe sepsis and other acute inflammatory conditions, serving patients with life-threatening immune-mediated diseases.
Similar biotechnology company
Bioxodes is a Belgian clinical-stage biotechnology company founded in 2013 and located in Gosselies. The firm focuses on developing breakthrough treatments for hemorrhagic stroke patients.
Similar biotechnology company
Calypso Biotech is a spin-off pharmaceutical company focusing on developing therapeutics for conditions such as celiac disease.
Biotech
Scarlet Therapeutics, founded in 2021 and headquartered in Bristol, United Kingdom, is developing a pioneering platform that generates novel red blood cell-based therapeutics to treat a wide range of diseases.
Similar biotechnology company
FibroGenesis is a U.S. biotechnology company focused on developing therapies for fibrosis and related fibrotic diseases. Its work is intended to serve patients with serious disorders in which excessive scar-tissue formation damages organs or tissues.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Cayuga Biotech and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Cayuga Biotechand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →